Filing Dossier Requirements and Key Differences from Registration

1. Key takeaways

The material requirements for filing applications are set out in Article 21 of the Implementation Rules. The structure is derived from the registration dossier but substantially narrower: the prescribed form states the same four contents required by Article 10(1), while the attachments are limited to four categories — applicant information together with the criminal record certificate and the debt-free certificate (items (1) and (2)), risk analysis material where applicable (item (3)), and items (4), (7), (11), (13) and (15) of Article 10(2) (the declaration of standing, the technical requirements, the specimens of labels and instructions for use, the overseas marketing evidence, and the patent proof or declaration). Clinical evaluation material, non-clinical evaluation material, the summary test report and the list of basic safety and performance principles are all absent from the mandatory filing list.

• The filing channel is a low-risk pathway with a four-category attachment list, not a reduced copy of the registration dossier.
• The ‘if any’ qualifier appears only in the risk analysis item of the filing list.
• Holders of a manufacturing licence and foreign trade operators enjoy the same waiver of items (1) and (2).
• Overseas marketing evidence remains mandatory even for filing, mirroring the registration regime.
• Simplified documents do not mean simplified post-filing obligations: Articles 16, 26 and 28 continue to apply.

2. Legal basis

The filing regime rests on Article 21 of the Implementation Rules, read together with the founding law, which defines the foreign trade operator and identifies which devices must follow the filing route. The formal review of a filing application is governed by a dedicated provision of the Implementation Rules, and the exemptions available to licence holders and foreign trade operators are written directly into the filing article.

3. Expert insights

First observation: the filing regime retains item (13), the overseas marketing evidence. Unlike registration, filing does not collect clinical or non-clinical evaluation material, yet it still requires overseas marketing evidence. This shows that the marketing-abroad prerequisite in Article 9(2) of the founding law applies uniformly to all device classes. Low risk does not mean a low threshold; it means a different type of threshold. Companies preparing filing applications sometimes assume that Class I-style simplicity removes documentary proof of foreign approval, and the text of Article 21 makes clear that it does not.

Second observation: the ‘if any’ wording appears only for the risk analysis material. Article 21(2)(3) refers to risk analysis material for the medical device where such material exists, making it the only technical item on the entire filing list carrying that qualifier. This gives the applicant room for judgement, but it also plants the seed of possible disputes: if ISAF considers that the material should have been provided, it can still demand it under Article 21(5). The prudent approach is to make an explicit, documented decision — either the risk analysis is submitted, or the dossier explains why none exists — rather than leaving the question open to the reviewer.

Third observation: foreign trade operators and licence holders enjoy the same waiver. Article 21(3) provides that an applicant who is the holder of a manufacturing licence or a foreign trade operator need not submit items (1) and (2). This mirrors the waiver logic of Article 10(3) for registration, with the qualifying circle widened to foreign trade operators — a business-friendly design of the low-risk channel. For companies that distribute devices rather than manufacture them, establishing foreign trade operator status is therefore the cheapest route to a leaner filing package.

Fourth observation: what is simplified is the paperwork, not the obligations after review. A filing is completed through formal review within 5 working days, but Article 24 provides for the issue of the filing notification, Article 26 allows the filing to be cancelled, Article 28 governs changes to filed particulars, and the obligations of registration holders and filing persons under Article 16 apply equally. The filing channel accelerates market entry; it does not suspend supervision. Post-market surveillance, record-keeping and change control continue to run with full force once the notification is issued.

4. Practical recommendations

• Work from both lists and subtract: do not prepare registration-grade material for a filing; it wastes cost and slows the timeline without adding approval value.
• Judge the risk analysis material against the ‘if any’ standard pragmatically: submit it where it exists and explain its absence where it does not, avoiding an obvious omission that invites a file request.
• Apply in the capacity of a foreign trade operator where possible: this waives items (1) and (2) and shortens the preparation of administrative documents.
• Obtain the overseas marketing evidence in advance: it is the longest-lead document on the filing list.

5. Verification checklist

• □ The prescribed form has been completed in accordance with Article 21(1)
• □ The four attachment categories are complete with no gaps
• □ Whether to submit the risk analysis material has been decided under the ‘if any’ principle
• □ It has been confirmed whether items (1) and (2) can be waived as a licence holder or foreign trade operator
• □ The overseas marketing evidence (item (13)) has been obtained
• □ The continuing obligations after filing (Articles 16, 26 and 28) are understood

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Macao, China. Our team prepares SSM-compliant dossiers, coordinates language and legalisation requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com